Back to search

Article

Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges

2022-12-05

Abstract excerpt

Age-related disorders of the musculoskeletal system including sarcopenia, osteoporosis and arthritis represent some of the most common chronic conditions worldwide, for which there remains a great clinical need to develop safer and more efficacious pharmacological treatments. Collectively, these conditions involve multiple tissues, including skeletal muscle, bone, articular cartilage and the synovium within the jo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9302d6eb-e4fc-5104-bcfb-78cdbd28ac14
DOI
10.20944/preprints202212.0079.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and ChallengesDOI 10.20944/preprints202212.0079.v1
Antisense oligonucleotide therapeutics targeting age-related diseasesSemantic proximity
Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development TherapeuticsSemantic proximity
Therapeutic antisense oligonucleotides for movement disordersSemantic proximity
Antisense oligonucleotides and their applications in rare neurological diseasesSemantic proximity
Antisense Oligonucleotide-Based Therapy for Neuromuscular DiseaseSemantic proximity
Therapeutic Potential of Tricyclo-DNA antisense oligonucleotidesSemantic proximity
Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical LandscapeSemantic proximity
Emerging Oligonucleotide Therapeutics for Rare Neuromuscular DiseasesSemantic proximity
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseasesSemantic proximity
FDA-Approved Oligonucleotide Therapies in 2017Semantic proximity
Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic FrontiersSemantic proximity
Research and Development of Oligonucleotide Therapeutics in Japan for Rare DiseasesSemantic proximity
Select a neighboring publication to make it the new centre.